Investment Landscape: Frontotemporal Dementia covers the current R&D investment,
clinical trial pipeline, and funding trends for Frontotemporal Dementia research.
Last updated: 2026-04-01 09:38 PT
Total Clinical Trials: 380
Active Trials (Recruiting/Active): 124
| Phase | Count |
|---|---|
| PHASE1 | 34 |
| PHASE1, PHASE2 | 12 |
| PHASE2 | 46 |
| PHASE2, PHASE3 | 3 |
| PHASE3 | 12 |
| PHASE4 | 8 |
| NA | 111 |
| Not Applicable | 144 |
| Status | Count |
|---|---|
| RECRUITING | 84 |
| ACTIVE_NOT_RECRUITING | 24 |
| NOT_YET_RECRUITING | 16 |
| COMPLETED | 172 |
| TERMINATED | 19 |
| WITHDRAWN | 10 |
Frontotemporal dementia represents an underserved area with only 380 total clinical trials. The small pipeline (12 Phase 3 trials) reflects diagnostic challenges and heterogeneity of the disorder. Investment in FTD remains significantly below Alzheimer's despite similar disease burden.
FTD research is benefiting from advances in tau PET imaging and fluid biomarkers. Progranulin replacement therapies are in development for the significant fraction of FTD cases with GRN mutations. Microglial modulation targeting TREM2 and other microglial receptors offers a novel approach. The overlap with ALS for C9orf72 cases is enabling cross-disease therapeutic development.
Only 3.2% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.
Last updated: 2026-04-01